Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Editorials”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,477 records · Page 82Linked to original sources
PubMed2002

Editorial.

Explore the source record for details and available documents.

Australia↗
PubMed2005

[Present status in studying immunotherapy for acute leukemia and its perspective--Editorial].

One of the important approaches for further prolonging remission duration and eradicating minimal residual disease in acute leukemia is immunotherapy. Four kinds of immunotherapy for acute leukemia are under investigation: (1) monoclonal antibodies, among them, Mylotarg (cytotoxic antibiotic calicheamicin linked to CD33 Mab) is given for the treatment of refractory or relapsed acute myeloid leukemia and molecular relapse in acute promyelocytic leukemia with good results, Campath-1H (antiCD52 Mab) is administered in the treatment of prolymphocytic leukemia and Rituximab (anti-CD20 Mab) in B-PLL with high complete remission rates. Other Mabs under preclinical and clinical trials include anti-IL-2 receptor Mab for the treatment of acute T lymphocytic leukemia, anti-220 kD Mab-6G7 for acute leukemias, recombinant immune toxin BL22 (anti-CD22) for hairy cell leukemia and Mabs labeled with radio-isotopes for different types of acute leukemias; (2) adoptive cellular immunotherapy using cytokine-induced killer cell, alloreactive NK cells, allogeneic or autologous leukemic-specific CD8(+) cytotoxic T lymphocytes, and other immune effector cells; (3) cytokines and other immune modulators comprising IL-2, IL-12, GM-CSF, CD40L, FLT-3L and thalidomide and its derivatives; (4) leukemia vaccines of several different formulations including antigen-specific, leukemia cell-based, leukemia antigen-pulsed dendritic cell (DC) and leukemia-derived DC vaccines, the latter two formulations are more attractive. In conclusion, up to now, the most effective example of immunotherapy in acute leukemia is provided by the administration of Mabs, and the majority of other approaches in immunotherapy for acute leukemia although promising, need further studies.

Acute Disease↗
PubMed2005

Editorial opinion: chemoinformatics - a ten year update.

The field of chemoinformatics was initially introduced to the pharmaceutical industry in 1995, with the first publication appearing in 1998. Since the introduction of the term and the practice, there has been much debate on the spelling and meaning of chemoinformatics. This article offers a single definition for chemoinformatics, which is supported by the publications of practitioners in the field. Several excellent papers that highlight the use of chemoinformatics are cited. This article, similarly to the first publication, will attempt to project a vision for this field.

Animals↗
PubMed2005

Editorial.

Explore the source record for details and available documents.

Aged↗
PubMed2005

[Editorial].

Explore the source record for details and available documents.

Editorial↗
PubMed2005

[Editorial].

Explore the source record for details and available documents.

Diabetes Mellitus, Type 2↗